[ XXXX and @entity158 ].

@entity1 @entity1643 @entity3522 @entity2493 @entity158 @entity1118
OBJECTIVE: To study analgesic possibilities of @entity2493 . MATERIAL AND METHODS: A study included 120 @entity1 , aged from 40 to 65 years, with @entity1643 . Duration of illness was not less than 12 weeks, the VAS score was >3. @entity1 were stratified into 4 groups (2 pairs of comparison). In the first pair, @entity1 of the main group (n=31) received a chondroprotector            with the addition of melaxen ( @entity2493 in dose 3 mg) and @entity1 of the control group (n=29) received only           . In the second pair, @entity1 of the control group (n=30) were treated with            and @entity3522 and @entity1 of the main group (n=30) received additionally melaxen. Treatment efficacy was assessed after 3 months for the first pair and after 1 month for the second pair. RESULTS: A significant reduction in @entity158 intensity at both resting state and movement was noted in main groups compared to controls. CONCLUSION: Due to its therapeutic efficacy and good tolerability, @entity2493 may be regarded as a drug of choice in the complex treatment of @entity1118 . Possible analgesic properties of @entity2493 and their mechanisms are discussed.
